Work

Donor-recipient age difference, not donor age alone, predicts outcomes in allogeneic hematopoietic stem cell transplantation for aplastic anemia

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background The impact of donor age on outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA) remains poorly defined. The prognostic value of donor–recipient age difference (DRAD) has rarely been explored. Objective To delineate the optimal donor age window and investigate the prognostic significance of the DRAD in AA patients undergoing allo-HSCT. Methods This retrospective study included 261 AA patients who received first allo-HSCT between 2018 and 2025. Patients were stratified into four groups based on donor age quartiles (G1: <20 yrs; G2: 20–29 yrs; G3: 29–38 yrs; G4: >38 yrs) and also by DRAD (DRAD1: <-10yrs; DRAD2: -10 to 10yrs; DRAD3: >+10 yrs). Primary endpoints were overall survival (OS), failure-free survival (FFS), and GVHD-free, relapse-free survival (GRFS). Results Donor age stratification alone did not significantly affect overall transplant outcomes. However, pairwise comparison showed that the G4 had significantly better OS than the G1 (5-year OS: 88.9% vs. 75.8%; P = 0.047). In multivariable Cox regression, donor age was not an independent predictor, but DRAD emerged as a critical factor. Compared with DRAD2 and DRAD3, DRAD1 was associated with significantly inferior neutrophil ( P = 0.008) and platelet ( P <0.001) engraftment, overall response ( P = 0.029), OS ( P <0.001), FFS ( P <0.001) and GRFS ( P =0.001). DRAD3 showed comparable OS, FFS, and GRFS to DRAD2, but had a significantly higher rate of EBV reactivation (74.6% vs. 59.1% and 59.0%, P = 0.040), suggesting that age-matched donor-recipient pairing may confer a favorable prognosis. Conclusion Donor age alone did not independently predict outcomes, whereas DRAD is a more impactful clinical parameter. A much younger donor (DRAD1) predicts poor outcomes, while age-matched donor-recipient pairing (DRAD2) offers the best balance of efficacy and safety. These findings raise the hypothesis that donor-recipient age matching may be preferable to simply pursuing the youngest donor. However, given the single-center nature of this study, external validation in independent cohorts is warranted before routine adoption in clinical practice.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7204121470
FWCI:
Cites: 34
Cited by:
Related to: 10